Podoplanin, Mouse, clone pMab-1
Monoclonal antibody pMab-1 recognizes human Podoplanin (PDPN; agrrus). Podoplanin is a small type_I transmembrane sialoglycoprotein expressed on a broad range of cell types and involved in platelet aggregation and tumor metastasis. The ca 38 kDa mouse protein was initially identified as a biomarker of lympatic endothelium, alveolar epithelium and glomerular podocytes. Expression has also been found in many tumors. However the functional role of PDPN is still poorly understood. Podoplanin consists of an extracellular domain, transmembrane domain and a cytoplasmic tail. In its extracellular domain it possesses a platelet aggregation stimulating (PLAG) domain. Podoplanin has got three PLAG domains of which PLAG3 is critical for binding with C-type lectin receptor-2 (CLEC-2). This PDPN specific receptor mediates platelet aggregation. This interaction is required to initiate and maintain separation of blood and lymphatic vessels and can be critical in process of cancer metastasis. This may lead to PDPN as possible therapeutic target. Antibody PMab-1 is produced against the platelet aggregation-stimulating domain of mouse PDPN and can be applied in western blotting, FACS and immunohistochemistry. Administration of PMab-1 in vivo reduces lymphangiogenesis in the corneal suture and ear wound healing models. PMab-1 also suppresses the infiltration of thioglycollate-induced macrophages at the site of wound healing. Furthermore, administration of PMab-1 leads to a significant suppression of the rejection reaction in the corneal transplantation model.
W: A reduced or non-reduced sample treatment and SDS-Page can be used. The band size is ~40 kDa.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA